Similar to other disease sites, prostate cancer has seen a surge in genetic testing options. To help address the role of genetic testing in prostate cancer disease management, the NCCN Clinical Practice Guidelines in Oncology were updated in February 2018 to include germline recommendations.
At the ACCC National Oncology Conference in October 2017, Brianne Joseph, LPI, brought the audience to their feet with a compelling message for those involved in cancer care.
The combination of the investigational drug quizartinib plus azacitidine (Vidaza) or low-dose cytarabine has substantial activity in patients with myeloid leukemias and FLT3 mutations.
We are proud to announce that the winner of the 2017 ONE Award is Laura Mulderrig, BSN, RN, OCN, a nurse in the clinical research unit at Fox Chase Cancer Center in Philadelphia.
In this issue, we feature a profile of the Taussig Cancer Center, Cleveland Clinic, OH, where, in my capacity as a nurse practitioner in the Department of Hematologic Oncology and Blood Disorders, my primary role is to diagnose and manage patients with multiple myeloma, amyloidosis, and other hematologic disorders.
As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation therapy is used to treat painful lesions or brain metastases.
To effectively address socioeconomic disparities in healthcare, it is critical that we improve our understanding of the material, psychosocial, and behavioral dimensions of financial well-being, said Reginald D. Tucker-Seeley, MA, ScM, ScD, at the 2017 AACR Science of Cancer Health Disparities Conference.
Although it is very curable when found and treated early on, early-stage cervical cancer may not cause any noticeable signs or symptoms. In advanced stages, however, the disease may cause vaginal bleeding or discharge that is abnormal for the patient.1
Advocacy usually begins with personal crisis and the need for support, but it eventually moves on to sharing experiences and information with others, speaking out in public forums, and working to influence change, suggested Musa Mayer, breast cancer survivor and advocate, at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal.
Beth Faiman, PhD, APRN-BC, AOCN, is an author, presenter, and educator on the topics of multiple myeloma, general cancer diagnosis and treatment, and management of skeletal and other cancer-related complications.
To sign up for our newsletter or print publications, please enter your contact information below.
Subscribe to recieve the free, monthly TON print publication and TON weekly e‑newsletter.